Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed
KOREA PACK and concurrent event ICPI Week (Int’l Cosmetic and Pharmaceutical Industry Week) will be held as hybrid events in 2022
The platform’s technology works as a compression algorithm for molecular testing
According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron
Organised by the Indian Stroke Association, it has attracted over 800 doctors from India and overseas
_256_384.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
Roche subsidiary TIB Molbiol rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant, as they continue to offer new and accurate detection solutions
The combination rapid antigen test quickly differentiates between SARS-CoV-2 and influenza viruses A and B infections, with results ready in less than 30 minutes, allowing informed decisions on patient and pandemic management decisions
These results demonstrate the potential benefits of heterologous boosting (mix-and-match). The article describing these results have been posted on medRxiv
Subscribe To Our Newsletter & Stay Updated
